原发性中枢神经系统淋巴瘤
本文综述免疫功能正常患者原发性中枢神经系统淋巴瘤(PCNSL)的临床表现、诊断分期及治疗进展。PCNSL诊断需高度警惕,大剂量甲氨蝶呤(MTX)为一线联合化疗 backbone,巩固策略包括放疗、维持治疗、非清髓化疗或清髓性治疗联合自体干细胞移植,但复发常见,5年生存率仅30%至40%。靶向B细胞受体通路及免疫调节药物为复发/难治患者带来新选择。
要点
- PCNSL诊断需高度警惕,临床表现取决于受累结构。
- 大剂量MTX是初治联合化疗的基石,完成MTX后常需巩固治疗。
- 复发常见,5年生存率仅30%至40%;BTK抑制剂和免疫调节药物对复发/难治有前景。
核心结论
- PCNSL预后较过去数十年显著改善,主要归因于大剂量MTX化疗的引入和广泛应用。
- 即使进行巩固治疗,复发仍常见,5年生存率仅为30%至40%。
- BTK抑制剂伊布替尼和免疫调节药物(来那度胺或泊马度胺)对复发/难治PCNSL显示出有前景的临床缓解率。
研究设计与样本
- 本文为综述,讨论免疫功能正常PCNSL患者的临床表现、检查分期方法、病理生理学理解进展及当前治疗策略。
主要发现
- PCNSL影响脑、脊髓、软脑膜或玻璃体视网膜,无全身受累证据。
- 治疗启动对最佳神经功能恢复和疾病控制具有时间敏感性。
- 巩固策略可包括放疗、维持治疗、非清髓化疗或清髓性治疗联合自体干细胞移植。
- 病理生理机制涉及B细胞受体通路激活、免疫逃逸和抑制性肿瘤免疫微环境。
临床怎么用
- PCNSL诊断需高度警惕,因临床表现取决于受累结构。
- 初治采用以大剂量MTX为基石的联合化疗,完成后常需巩固治疗以延长缓解持续时间。
- 复发/难治患者可考虑伊布替尼或免疫调节药物(来那度胺或泊马度胺)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary central nervous system lymphoma (PCNSL) is a rare extranodal lymphomatous malignancy that affects the brain, spinal cord, leptomeninges, or vitreoretinal space, without evidence of systemic involvement. The diagnosis of PCNSL requires a high level of suspicion because clinical presentation varies depending upon involved structures. Initiation of treatment is time sensitive for optimal neurologic recovery and disease control. In general, the prognosis of PCNSL has improved significantly over the past few decades, largely as a result of the introduction and widespread use of high-dose methotrexate (MTX) chemotherapy, which is considered the backbone of first-line polychemotherapy treatment. Upon completion of MTX-based treatment, a consolidation strategy is often required to prolong duration of response. Consolidation can consist of radiation, maintenance therapy, nonmyeloablative chemotherapy, or myeloablative treatment followed by autologous stem cell transplant. Unfortunately, even with consolidation, relapse is common, and 5-year survival rates stand at only 30% to 40%. Novel insights into the pathophysiology of PCNSL have identified key mechanisms in tumor pathogenesis, including activation of the B-cell receptor pathway, immune evasion, and a suppressed tumor immune microenvironment. These insights have led to the identification of novel small molecules targeting these aberrant pathways. The Bruton tyrosine kinase inhibitor ibrutinib and immunomodulatory drugs (lenalidomide or pomalidomide) have shown promising clinical response rates for relapsed/refractory PCNSL and are increasingly used for the treatment of recurrent disease. This review provides a discussion of the clinical presentation of PCNSL, the approach to work-up and staging, and an overview of recent advancements in the understanding of the pathophysiology and current treatment strategies for immunocompetent patients.
引用
- Schaff LR, Grommes C. Primary central nervous system lymphoma. Blood. 2022. PMID: 34699590. doi:10.1182/blood.2020008377
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。